| Antimicrobial Agent | Susceptibility Profile | Clinical Interpretation |
|---|---|---|
| Amikacin | Sensitive | <=2 |
| Amoxicillin/Clavulanic acid | Intermediate | 16 |
| Ampicillin | Resistant | >=32 |
| Cefepime | Resistant | >=64 |
| Cefotaxime | Resistant | >=256 |
| Ceftazidime | Resistant | >=256 |
| Ceftriaxone | Resistant | >=64 |
| Cefuroxime | Resistant | >=64 |
| Ciprofloxacin | Resistant | >=4 |
| Colistin | Intermediate | 0.5 |
| Ertapenem | Sensitive | <=0.5 |
| Gentamicin | Sensitive | <=1 |
| Imipenem | Sensitive | <=0.25 |
| Levofloxacin | Resistant | 16 |
| Meropenem | Sensitive | <=0.25 |
| Nalidixic acid | Resistant | >=32 |
| Nitrofurantoin | Sensitive | <=16 |
| Piperacillin/Tazobactam | Intermediate | 64 |
| Tobramycin | Sensitive | 1 |
| Trimethoprim/Sulfamethoxazole | Resistant | >=320 |
| Resistant Gene Track | Detection Methodology | NCBI Genome Accession |
|---|---|---|